Trastzumab Deruxtecan + Bevacizumab + Platinum Based Chemotherapy
Phase 2Recruiting 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Ovarian Cancer
Conditions
Ovarian Cancer, Ovarian Carcinoma, Recurrent, Ovarian Cancer Metastatic Recurrent, Ovarian Cancer (OvCa)
Trial Timeline
Dec 30, 2025 → Dec 31, 2030
NCT ID
NCT07340164About Trastzumab Deruxtecan + Bevacizumab + Platinum Based Chemotherapy
Trastzumab Deruxtecan + Bevacizumab + Platinum Based Chemotherapy is a phase 2 stage product being developed by Daiichi Sankyo for Ovarian Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07340164. Target conditions include Ovarian Cancer, Ovarian Carcinoma, Recurrent, Ovarian Cancer Metastatic Recurrent.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07340164 | Phase 2 | Recruiting |
Competing Products
20 competing products in Ovarian Cancer